Industry Research Reports

Home > Reports > Medical Devices & Consumables > Global Radioligand Therapy Market Research Report 2026

Global Radioligand Therapy Market Research Report 2026

Industry: Medical Devices & Consumables

Published Date: 2026-04-17

Pages: 103 Pages

Report ld: 6467105

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Radioligand Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The North American market for Radioligand Therapy is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Radioligand Therapy is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Radioligand Therapy in Neuroendocrine Neoplasms is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG, Curium Pharma, Precirix, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Radioligand Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radioligand Therapy. The Radioligand Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Radioligand Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Radioligand Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

MARKET SEGMENTATION

By Company

Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides

Segment by Application

Neuroendocrine Neoplasms
Prostate Cancer

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Radioligand Therapy companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Radioligand Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Actinium 225 (Ac-225)

1.2.3 Lutetium 177 (Lu-177)

1.2.4 Gallium 68 (Ga-68)

1.2.5 Fluorine 18 (F-18)

1.2.6 Other Radionuclides

1.3 Market by Application

1.3.1 Global Radioligand Therapy Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Neuroendocrine Neoplasms

1.3.3 Prostate Cancer

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Radioligand Therapy Market Perspective (2021–2032)

2.2 Global Radioligand Therapy Growth Trends by Region

2.2.1 Global Radioligand Therapy Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Radioligand Therapy Historic Market Size by Region (2021–2026)

2.2.3 Radioligand Therapy Forecasted Market Size by Region (2027–2032)

2.3 Radioligand Therapy Market Dynamics

2.3.1 Radioligand Therapy Industry Trends

2.3.2 Radioligand Therapy Market Drivers

2.3.3 Radioligand Therapy Market Challenges

2.3.4 Radioligand Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Radioligand Therapy Players by Revenue

3.1.1 Global Top Radioligand Therapy Players by Revenue (2021–2026)

3.1.2 Global Radioligand Therapy Revenue Market Share by Players (2021–2026)

3.2 Global Top Radioligand Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Radioligand Therapy Revenue

3.4 Global Radioligand Therapy Market Concentration Ratio

3.4.1 Global Radioligand Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2025

3.5 Global Key Players of Radioligand Therapy Head Offices and Areas Served

3.6 Global Key Players of Radioligand Therapy, Products and Applications

3.7 Global Key Players of Radioligand Therapy, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Radioligand Therapy Breakdown Data by Type

4.1 Global Radioligand Therapy Historic Market Size by Type (2021–2026)

4.2 Global Radioligand Therapy Forecasted Market Size by Type (2027–2032)

5 Radioligand Therapy Breakdown Data by Application

5.1 Global Radioligand Therapy Historic Market Size by Application (2021–2026)

5.2 Global Radioligand Therapy Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Radioligand Therapy Market Size (2021–2032)

6.2 North America Radioligand Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Radioligand Therapy Market Size by Country (2021–2026)

6.4 North America Radioligand Therapy Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Radioligand Therapy Market Size (2021–2032)

7.2 Europe Radioligand Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Radioligand Therapy Market Size by Country (2021–2026)

7.4 Europe Radioligand Therapy Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Radioligand Therapy Market Size (2021–2032)

8.2 Asia-Pacific Radioligand Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Radioligand Therapy Market Size by Region (2021–2026)

8.4 Asia-Pacific Radioligand Therapy Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Radioligand Therapy Market Size (2021–2032)

9.2 Latin America Radioligand Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Radioligand Therapy Market Size by Country (2021–2026)

9.4 Latin America Radioligand Therapy Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Radioligand Therapy Market Size (2021–2032)

10.2 Middle East & Africa Radioligand Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Radioligand Therapy Market Size by Country (2021–2026)

10.4 Middle East & Africa Radioligand Therapy Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Radioligand Therapy Introduction

11.1.4 Novartis Revenue in Radioligand Therapy Business (2021–2026)

11.1.5 Novartis Recent Development

11.2 Advanced Accelerator Applications

11.2.1 Advanced Accelerator Applications Company Details

11.2.2 Advanced Accelerator Applications Business Overview

11.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction

11.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2021–2026)

11.2.5 Advanced Accelerator Applications Recent Development

11.3 Mercy Radiology

11.3.1 Mercy Radiology Company Details

11.3.2 Mercy Radiology Business Overview

11.3.3 Mercy Radiology Radioligand Therapy Introduction

11.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2021–2026)

11.3.5 Mercy Radiology Recent Development

11.4 POINT Biopharma Global Inc

11.4.1 POINT Biopharma Global Inc Company Details

11.4.2 POINT Biopharma Global Inc Business Overview

11.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction

11.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2021–2026)

11.4.5 POINT Biopharma Global Inc Recent Development

11.5 Fusion Pharma

11.5.1 Fusion Pharma Company Details

11.5.2 Fusion Pharma Business Overview

11.5.3 Fusion Pharma Radioligand Therapy Introduction

11.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2021–2026)

11.5.5 Fusion Pharma Recent Development

11.6 Telix Pharmaceuticals Ltd

11.6.1 Telix Pharmaceuticals Ltd Company Details

11.6.2 Telix Pharmaceuticals Ltd Business Overview

11.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction

11.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2021–2026)

11.6.5 Telix Pharmaceuticals Ltd Recent Development

11.7 Lantheus Holdings, Inc

11.7.1 Lantheus Holdings, Inc Company Details

11.7.2 Lantheus Holdings, Inc Business Overview

11.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction

11.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2021–2026)

11.7.5 Lantheus Holdings, Inc Recent Development

11.8 Bayer AG

11.8.1 Bayer AG Company Details

11.8.2 Bayer AG Business Overview

11.8.3 Bayer AG Radioligand Therapy Introduction

11.8.4 Bayer AG Revenue in Radioligand Therapy Business (2021–2026)

11.8.5 Bayer AG Recent Development

11.9 Curium Pharma

11.9.1 Curium Pharma Company Details

11.9.2 Curium Pharma Business Overview

11.9.3 Curium Pharma Radioligand Therapy Introduction

11.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2021–2026)

11.9.5 Curium Pharma Recent Development

11.10 Precirix

11.10.1 Precirix Company Details

11.10.2 Precirix Business Overview

11.10.3 Precirix Radioligand Therapy Introduction

11.10.4 Precirix Revenue in Radioligand Therapy Business (2021–2026)

11.10.5 Precirix Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Radioligand Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Actinium 225 (Ac-225)

Table 3. Key Players of Lutetium 177 (Lu-177)

Table 4. Key Players of Gallium 68 (Ga-68)

Table 5. Key Players of Fluorine 18 (F-18)

Table 6. Key Players of Other Radionuclides

Table 7. Global Radioligand Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Radioligand Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 9. Global Radioligand Therapy Market Size by Region (US$ Million), 2021–2026

Table 10. Global Radioligand Therapy Market Share by Region (2021–2026)

Table 11. Global Radioligand Therapy Forecasted Market Size by Region (US$ Million), 2027–2032

Table 12. Global Radioligand Therapy Market Share by Region (2027–2032)

Table 13. Radioligand Therapy Market Trends

Table 14. Radioligand Therapy Market Drivers

Table 15. Radioligand Therapy Market Challenges

Table 16. Radioligand Therapy Market Restraints

Table 17. Global Radioligand Therapy Revenue by Players (US$ Million), 2021–2026

Table 18. Global Radioligand Therapy Market Share by Players (2021–2026)

Table 19. Global Top Radioligand Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Radioligand Therapy Revenue, 2025

Table 20. Ranking of Global Top Radioligand Therapy Companies by Revenue (US$ Million) in 2025

Table 21. Global 5 Largest Players Market Share by Radioligand Therapy Revenue (CR5 and HHI), 2021–2026

Table 22. Global Key Players of Radioligand Therapy, Headquarters and Area Served

Table 23. Global Key Players of Radioligand Therapy, Products and Applications

Table 24. Global Key Players of Radioligand Therapy, Date of General Availability (GA)

Table 25. Mergers and Acquisitions, Expansion Plans

Table 26. Global Radioligand Therapy Market Size by Type (US$ Million), 2021–2026

Table 27. Global Radioligand Therapy Revenue Market Share by Type (2021–2026)

Table 28. Global Radioligand Therapy Forecasted Market Size by Type (US$ Million), 2027–2032

Table 29. Global Radioligand Therapy Revenue Market Share by Type (2027–2032)

Table 30. Global Radioligand Therapy Market Size by Application (US$ Million), 2021–2026

Table 31. Global Radioligand Therapy Revenue Market Share by Application (2021–2026)

Table 32. Global Radioligand Therapy Forecasted Market Size by Application (US$ Million), 2027–2032

Table 33. Global Radioligand Therapy Revenue Market Share by Application (2027–2032)

Table 34. North America Radioligand Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. North America Radioligand Therapy Market Size by Country (US$ Million), 2021–2026

Table 36. North America Radioligand Therapy Market Size by Country (US$ Million), 2027–2032

Table 37. Europe Radioligand Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 38. Europe Radioligand Therapy Market Size by Country (US$ Million), 2021–2026

Table 39. Europe Radioligand Therapy Market Size by Country (US$ Million), 2027–2032

Table 40. Asia-Pacific Radioligand Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 41. Asia-Pacific Radioligand Therapy Market Size by Region (US$ Million), 2021–2026

Table 42. Asia-Pacific Radioligand Therapy Market Size by Region (US$ Million), 2027–2032

Table 43. Latin America Radioligand Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Latin America Radioligand Therapy Market Size by Country (US$ Million), 2021–2026

Table 45. Latin America Radioligand Therapy Market Size by Country (US$ Million), 2027–2032

Table 46. Middle East & Africa Radioligand Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Middle East & Africa Radioligand Therapy Market Size by Country (US$ Million), 2021–2026

Table 48. Middle East & Africa Radioligand Therapy Market Size by Country (US$ Million), 2027–2032

Table 49. Novartis Company Details

Table 50. Novartis Business Overview

Table 51. Novartis Radioligand Therapy Product

Table 52. Novartis Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 53. Novartis Recent Development

Table 54. Advanced Accelerator Applications Company Details

Table 55. Advanced Accelerator Applications Business Overview

Table 56. Advanced Accelerator Applications Radioligand Therapy Product

Table 57. Advanced Accelerator Applications Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 58. Advanced Accelerator Applications Recent Development

Table 59. Mercy Radiology Company Details

Table 60. Mercy Radiology Business Overview

Table 61. Mercy Radiology Radioligand Therapy Product

Table 62. Mercy Radiology Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 63. Mercy Radiology Recent Development

Table 64. POINT Biopharma Global Inc Company Details

Table 65. POINT Biopharma Global Inc Business Overview

Table 66. POINT Biopharma Global Inc Radioligand Therapy Product

Table 67. POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 68. POINT Biopharma Global Inc Recent Development

Table 69. Fusion Pharma Company Details

Table 70. Fusion Pharma Business Overview

Table 71. Fusion Pharma Radioligand Therapy Product

Table 72. Fusion Pharma Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 73. Fusion Pharma Recent Development

Table 74. Telix Pharmaceuticals Ltd Company Details

Table 75. Telix Pharmaceuticals Ltd Business Overview

Table 76. Telix Pharmaceuticals Ltd Radioligand Therapy Product

Table 77. Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 78. Telix Pharmaceuticals Ltd Recent Development

Table 79. Lantheus Holdings, Inc Company Details

Table 80. Lantheus Holdings, Inc Business Overview

Table 81. Lantheus Holdings, Inc Radioligand Therapy Product

Table 82. Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 83. Lantheus Holdings, Inc Recent Development

Table 84. Bayer AG Company Details

Table 85. Bayer AG Business Overview

Table 86. Bayer AG Radioligand Therapy Product

Table 87. Bayer AG Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 88. Bayer AG Recent Development

Table 89. Curium Pharma Company Details

Table 90. Curium Pharma Business Overview

Table 91. Curium Pharma Radioligand Therapy Product

Table 92. Curium Pharma Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 93. Curium Pharma Recent Development

Table 94. Precirix Company Details

Table 95. Precirix Business Overview

Table 96. Precirix Radioligand Therapy Product

Table 97. Precirix Revenue in Radioligand Therapy Business (US$ Million), 2021–2026

Table 98. Precirix Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

Table 102. Authors List of This Report

List of Figures

Figure 1. Radioligand Therapy Picture

Figure 2. Global Radioligand Therapy Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Radioligand Therapy Market Share by Type: 2025 vs 2032

Figure 4. Actinium 225 (Ac-225) Features

Figure 5. Lutetium 177 (Lu-177) Features

Figure 6. Gallium 68 (Ga-68) Features

Figure 7. Fluorine 18 (F-18) Features

Figure 8. Other Radionuclides Features

Figure 9. Global Radioligand Therapy Market Size by Application (US$ Million), 2021–2032

Figure 10. Global Radioligand Therapy Market Share by Application: 2025 vs 2032

Figure 11. Neuroendocrine Neoplasms Case Studies

Figure 12. Prostate Cancer Case Studies

Figure 13. Radioligand Therapy Report Years Considered

Figure 14. Global Radioligand Therapy Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 15. Global Radioligand Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Radioligand Therapy Market Share by Region: 2025 vs 2032

Figure 17. Global Radioligand Therapy Market Share by Players in 2025

Figure 18. Global Radioligand Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Radioligand Therapy Revenue in 2025

Figure 20. North America Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. North America Radioligand Therapy Market Share by Country (2021–2032)

Figure 22. United States Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Canada Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe Radioligand Therapy Market Share by Country (2021–2032)

Figure 26. Germany Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. France Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. U.K. Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Italy Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Russia Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Ireland Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific Radioligand Therapy Market Share by Region (2021–2032)

Figure 34. China Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Japan Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. South Korea Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Southeast Asia Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. India Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Australia & New Zealand Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America Radioligand Therapy Market Share by Country (2021–2032)

Figure 42. Mexico Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Brazil Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa Radioligand Therapy Market Share by Country (2021–2032)

Figure 46. Israel Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Saudi Arabia Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. UAE Radioligand Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Novartis Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 50. Advanced Accelerator Applications Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 51. Mercy Radiology Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 52. POINT Biopharma Global Inc Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 53. Fusion Pharma Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 54. Telix Pharmaceuticals Ltd Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 55. Lantheus Holdings, Inc Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 56. Bayer AG Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 57. Curium Pharma Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 58. Precirix Revenue Growth Rate in Radioligand Therapy Business (2021–2026)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Radioligand Therapy market? zhanKai

The top companies in the global Radioligand Therapy market are Novartis、Advanced Accelerator Applications、Mercy Radiology.

Related Reports

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-06-16
Pages: 110
USD 3950.00
(Single User License)
Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Radioligand Therapy market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-02
Pages: 80
USD 4250.00
(Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-02
Pages: 128
USD 4900.00
(Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 91
USD 3950.00
(Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-01
Pages: 79
USD 2900.00
(Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-02-06
Pages: 82
USD 2900.00
(Single User License)
Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Radioligand Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 109
USD 3950.00
(Single User License)

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-06-16
Pages: 110
USD 3950.00 (Single User License)
Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Radioligand Therapy market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-02
Pages: 80
USD 4250.00 (Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-02
Pages: 128
USD 4900.00 (Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 91
USD 3950.00 (Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-01
Pages: 79
USD 2900.00 (Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-02-06
Pages: 82
USD 2900.00 (Single User License)
Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Radioligand Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 109
USD 3950.00 (Single User License)